These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

228 related articles for article (PubMed ID: 34709898)

  • 1. Alzheimer's drugs: Does reducing amyloid work?
    Thambisetty M; Howard R; Glymour MM; Schneider LS
    Science; 2021 Oct; 374(6567):544-545. PubMed ID: 34709898
    [No Abstract]   [Full Text] [Related]  

  • 2. Alzheimer's drugs: Does reducing amyloid work?-Response.
    Selkoe DJ
    Science; 2021 Oct; 374(6567):545-546. PubMed ID: 34709920
    [No Abstract]   [Full Text] [Related]  

  • 3. Alzheimer's disease: where next for anti-amyloid therapies?
    Hardy J; De Strooper B
    Brain; 2017 Apr; 140(4):853-855. PubMed ID: 28375461
    [No Abstract]   [Full Text] [Related]  

  • 4. [The Convergence of Alzheimer's Disease Pathogenesis Concepts].
    Kozin SA; Makarov AA
    Mol Biol (Mosk); 2019; 53(6):1020-1028. PubMed ID: 31876280
    [TBL] [Abstract][Full Text] [Related]  

  • 5. An anti-amyloid therapy works for Alzheimer's disease: why has it taken so long and what is next?
    Hardy J; Mummery C
    Brain; 2023 Apr; 146(4):1240-1242. PubMed ID: 36797987
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Genistein: A Dual Inhibitor of Both Amyloid β and Human Islet Amylin Peptides.
    Ren B; Liu Y; Zhang Y; Cai Y; Gong X; Chang Y; Xu L; Zheng J
    ACS Chem Neurosci; 2018 May; 9(5):1215-1224. PubMed ID: 29432676
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Elucidating the Structures of Amyloid Oligomers with Macrocyclic β-Hairpin Peptides: Insights into Alzheimer's Disease and Other Amyloid Diseases.
    Kreutzer AG; Nowick JS
    Acc Chem Res; 2018 Mar; 51(3):706-718. PubMed ID: 29508987
    [TBL] [Abstract][Full Text] [Related]  

  • 8. An Ethical Argument for Ending Human Trials of Amyloid-Lowering Therapies in Alzheimer's Disease.
    Daly T; Herrup K; Espay AJ
    AJOB Neurosci; 2024; 15(2):80-81. PubMed ID: 36197130
    [TBL] [Abstract][Full Text] [Related]  

  • 9. β-Amyloid Accumulation Slows Earlier than Expected in Preclinical Alzheimer's Disease Patients.
    Camara H; De-Souza EA
    J Neurosci; 2018 Oct; 38(43):9123-9125. PubMed ID: 30355622
    [No Abstract]   [Full Text] [Related]  

  • 10. Anti-Amyloid-β Single-Chain Antibody Brain Delivery Via AAV Reduces Amyloid Load But May Increase Cerebral Hemorrhages in an Alzheimer's Disease Mouse Model.
    Kou J; Kim H; Pattanayak A; Song M; Lim JE; Taguchi H; Paul S; Cirrito JR; Ponnazhagan S; Fukuchi K
    J Alzheimers Dis; 2011; 27(1):23-38. PubMed ID: 21709371
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A good marker does not mean a good target for clinical trials in Alzheimer's disease: the amyloid hypothesis questioned.
    Modrego P; Lobo A
    Neurodegener Dis Manag; 2019 Jun; 9(3):119-121. PubMed ID: 31116074
    [No Abstract]   [Full Text] [Related]  

  • 12. Understanding the Amyloid Hypothesis in Alzheimer's Disease.
    Paroni G; Bisceglia P; Seripa D
    J Alzheimers Dis; 2019; 68(2):493-510. PubMed ID: 30883346
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The amyloid proteins of Alzheimer's disease as potential targets for drug therapy.
    Caputo CB; Salama AI
    Neurobiol Aging; 1989; 10(5):451-61. PubMed ID: 2682322
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Alzheimer's Disease "Non-amyloidogenic" p3 Peptide Revisited: A Case for Amyloid-α.
    Kuhn AJ; Abrams BS; Knowlton S; Raskatov JA
    ACS Chem Neurosci; 2020 Jun; 11(11):1539-1544. PubMed ID: 32412731
    [TBL] [Abstract][Full Text] [Related]  

  • 15. BIIB042, a novel γ-secretase modulator, reduces amyloidogenic Aβ isoforms in primates and rodents and plaque pathology in a mouse model of Alzheimer's disease.
    Scannevin RH; Chollate S; Brennan MS; Snodgrass-Belt PA; Peng H; Xu L; Jung MY; Bussiere T; Arastu MF; Talreja T; Xin Z; Dunstan RW; Fahrer D; Rohde E; Dunah AW; Wang J; Kumaravel G; Taveras AG; Moore Arnold H; Rhodes KJ
    Neuropharmacology; 2016 Apr; 103():57-68. PubMed ID: 26690893
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Amyloid Peptide Scaffolds Coordinate with Alzheimer's Disease Drugs.
    Jonnalagadda SVR; Gerace AJ; Thai K; Johnson J; Tsimenidis K; Jakubowski JM; Shen C; Henderson KJ; Tamamis P; Gkikas M
    J Phys Chem B; 2020 Jan; 124(3):487-503. PubMed ID: 31881810
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Biophenols pharmacology against the amyloidogenic activity in Alzheimer's disease.
    Omar SH
    Biomed Pharmacother; 2017 May; 89():396-413. PubMed ID: 28249241
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Application of optogenetic Amyloid-β distinguishes between metabolic and physical damages in neurodegeneration.
    Lim CH; Kaur P; Teo E; Lam VYM; Zhu F; Kibat C; Gruber J; Mathuru AS; Tolwinski NS
    Elife; 2020 Mar; 9():. PubMed ID: 32228858
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Amyloid forming proteases: therapeutic targets for Alzheimer's disease.
    Schimmöller F; Higaki JN; Cordell B
    Curr Pharm Des; 2002; 8(28):2521-31. PubMed ID: 12369937
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The amyloid precursor protein (APP) processing as a biological link between Alzheimer's disease and cancer.
    Galvão F; Grokoski KC; da Silva BB; Lamers ML; Siqueira IR
    Ageing Res Rev; 2019 Jan; 49():83-91. PubMed ID: 30500566
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.